Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia
NCT07182760 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-09-19
Summary
Investigate prevalence of splenomegally in patients with isolated thrombocytopenia.
Asess effect of splenomegally in clinical picture ,Complication, treatment response and disease outcome To explain possible causes of splenomegally in patients with isolated thrombocytopenia
Conditions
- Primary Immune Thrombocytopenic Purpura
- Amegakaryocytic Aplasia
- Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia)
- Lymphoproliferative Disorder With Secondary ITP
- Autoimmune Diseases With Secondary ITP
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-10-31
- Primary Completion
- 2027-05-31
- Completion
- 2027-05-31
More Related Trials
-
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
NCT07268898 ·Status: NOT_YET_RECRUITING
-
Explore the Relationship Between Platelet Count and Bleeding Score in ITP
NCT06273956 ·Status: RECRUITING
-
IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
NCT04482777 ·Status: UNKNOWN
-
Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients
NCT06979765 ·Status: RECRUITING ·Phase: NA
-
Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010
NCT06466824 ·Status: NOT_YET_RECRUITING
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
NCT00005570 ·Status: COMPLETED
-
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1
-
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
NCT04003220 ·Status: UNKNOWN
-
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP
NCT04917679 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
NCT02227693 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
NCT05046327 ·Status: WITHDRAWN ·Phase: PHASE3
-
Value of Platelet Indices as Predictive Factor in Thrombocytopenia
NCT05116033 ·Status: UNKNOWN
-
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
NCT05093257 ·Status: UNKNOWN
-
Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia
NCT06715215 ·Status: RECRUITING ·Phase: NA
-
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
NCT06531018 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Herombopag + rhTPO in Severe Immune Thrombocytopenia
NCT05328804 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00540423 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
NCT01129024 ·Status: TERMINATED ·Phase: PHASE2
-
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
NCT04800458 ·Status: RECRUITING ·Phase: NA
-
The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia
NCT05468866 ·Status: UNKNOWN ·Phase: NA
-
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Immune Thrombocytopenia Pathogenesis:
NCT02042560 ·Status: COMPLETED
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
NCT03771378 ·Status: UNKNOWN ·Phase: PHASE4
-
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
NCT04518475 ·Status: RECRUITING ·Phase: PHASE4